BioCentury
ARTICLE | Product Development

Targeting Akt & MEK

June 22, 2009 7:00 AM UTC

By targeting both Akt and MEK, AstraZeneca plc (LSE:AZN; NYSE:AZN) and Merck & Co. Inc. (NYSE:MRK) hope to create a cancer therapy that blocks two separate signaling pathways involved in cell prolifer...